Mr. Alexander L. Johnson

Pres of Patient and Testing Services

Mr. Abhishek  Jain

Chief Financial Officer, Vice President, Corporation Controller, Principal Financial Officer & Principal Accounting Officer

Ms. Sasha  King M.B.A.

Executive Officer

Mr. Marcel  Konrad

Senior Vice President of Fin. & Accounting

Mr. Ian  Cooney

Vice President of Investor Relations

Dr. Reginald  Seeto

Pres, Chief Executive Officer & Director

Dr. Peter  Maag Ph.D.

Executive Director

Ms. Marica  Grskovic Ph.D.

Chief Operating Officer

Mr. Abraham  Ronai Esq.

Gen. Counsel, Chief Admin. & Legal Officer and Sec.

Dr. Reginald  Seeto M.D., MBBS

Dr. Mickey Y. Kim M.D.

Senior Vice President of Corporation Devel. & Head of Global Product

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

CareDx, Inc. (NASDAQ:CDNA ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Greg Chodaczek - IR Reginald Seeto - CEO Abhishek Jain - Interim CFO Conference Call Participants Andrew Cooper - Raymond James Matthew Sykes - Goldman Sachs Mason Carrico - Stephens Alex Nowak - Craig-Hallum Capital Group Mark Massaro - BTIG Yi Chen - H.C. Wainright Operator Good day, ladies and gentlemen, and welcome to the CareDx, Incorporated Fourth Quarter 2022 Earnings Conference Call.

CareDx, Inc. (CDNA) Q4 2022 Results Earnings Call Transcript

CareDx (CDNA) delivered earnings and revenue surprises of -16.67% and 0.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Reports Q4 Loss, Tops Revenue Estimates

The growth-focused money manager is making moves.

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

CDNA's share repurchase program will reduce outstanding shares by 8% based on current prices. This and management's short-term profitability ambitions warrant a rating upgrade. The company has a strong balance sheet, with enough dry powder to leverage itself into profitability as it gradually winds down its growth initiatives.

CareDx: What To Make Of The New Share Repurchase Program (Rating Upgrade)

CareDx (CDNA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why CareDx (CDNA) Could be Great Choice for a Bottom Fisher

Powered by AI

CareDx, Inc

9.14